Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon
Formato:	article
Lenguaje:	EN
Publicado:	Korean Diabetes Association 2021
Materias:	diabetes mellitus, type 2 drug therapy, combination glycated hemoglobin a korea metformin vildagliptin Diseases of the endocrine glands. Clinical endocrinology RC648-665
Acceso en línea:	https://doaj.org/article/cecc7af70b0d46858cf7813f8e5cd318
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cecc7af70b0d46858cf7813f8e5cd318
record_format	dspace
spelling	oai:doaj.org-article:cecc7af70b0d46858cf7813f8e5cd3182021-12-01T05:07:51ZLong-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus2233-60792233-608710.4093/dmj.2020.0173https://doaj.org/article/cecc7af70b0d46858cf7813f8e5cd3182021-11-01T00:00:00Zhttp://www.e-dmj.org/upload/pdf/dmj-2020-0173.pdfhttps://doaj.org/toc/2233-6079https://doaj.org/toc/2233-6087We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.Soon-Jib YooSang-Ah ChangTae Seo SohnHyuk-Sang KwonJong Min LeeSungdae MoonPieter ProotPäivi M PaldániusKun Ho YoonKorean Diabetes Associationarticlediabetes mellitus, type 2drug therapy, combinationglycated hemoglobin akoreametforminvildagliptinDiseases of the endocrine glands. Clinical endocrinologyRC648-665ENDiabetes & Metabolism Journal, Vol 45, Iss 6, Pp 954-959 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetes mellitus, type 2 drug therapy, combination glycated hemoglobin a korea metformin vildagliptin Diseases of the endocrine glands. Clinical endocrinology RC648-665
spellingShingle	diabetes mellitus, type 2 drug therapy, combination glycated hemoglobin a korea metformin vildagliptin Diseases of the endocrine glands. Clinical endocrinology RC648-665 Soon-Jib Yoo Sang-Ah Chang Tae Seo Sohn Hyuk-Sang Kwon Jong Min Lee Sungdae Moon Pieter Proot Päivi M Paldánius Kun Ho Yoon Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
description	We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.
format	article
author	Soon-Jib Yoo Sang-Ah Chang Tae Seo Sohn Hyuk-Sang Kwon Jong Min Lee Sungdae Moon Pieter Proot Päivi M Paldánius Kun Ho Yoon
author_facet	Soon-Jib Yoo Sang-Ah Chang Tae Seo Sohn Hyuk-Sang Kwon Jong Min Lee Sungdae Moon Pieter Proot Päivi M Paldánius Kun Ho Yoon
author_sort	Soon-Jib Yoo
title	Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
title_short	Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
title_full	Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
title_fullStr	Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
title_full_unstemmed	Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
title_sort	long-term glycaemic durability of early combination therapy strategy versus metformin monotherapy in korean patients with newly diagnosed type 2 diabetes mellitus
publisher	Korean Diabetes Association
publishDate	2021
url	https://doaj.org/article/cecc7af70b0d46858cf7813f8e5cd318
work_keys_str_mv	AT soonjibyoo longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT sangahchang longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT taeseosohn longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT hyuksangkwon longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT jongminlee longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT sungdaemoon longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT pieterproot longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT paivimpaldanius longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus AT kunhoyoon longtermglycaemicdurabilityofearlycombinationtherapystrategyversusmetforminmonotherapyinkoreanpatientswithnewlydiagnosedtype2diabetesmellitus
_version_	1718405569864269824

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus

Ejemplares similares